1. Home
  2. SCSC vs IOVA Comparison

SCSC vs IOVA Comparison

Compare SCSC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ScanSource Inc.

SCSC

ScanSource Inc.

HOLD

Current Price

$40.38

Market Cap

909.7M

Sector

Technology

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.62

Market Cap

881.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCSC
IOVA
Founded
1992
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
909.7M
881.3M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
SCSC
IOVA
Price
$40.38
$2.62
Analyst Decision
Hold
Buy
Analyst Count
1
12
Target Price
$43.00
$10.45
AVG Volume (30 Days)
158.6K
11.8M
Earning Date
02-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
1.79
N/A
EPS
3.20
N/A
Revenue
$3,004,880,000.00
$250,425,000.00
Revenue This Year
$5.40
$60.71
Revenue Next Year
$5.34
$59.52
P/E Ratio
$12.73
N/A
Revenue Growth
N/A
175.62
52 Week Low
$28.75
$1.64
52 Week High
$51.66
$6.50

Technical Indicators

Market Signals
Indicator
SCSC
IOVA
Relative Strength Index (RSI) 49.39 55.64
Support Level $39.34 $2.21
Resistance Level $41.78 $2.72
Average True Range (ATR) 1.08 0.19
MACD 0.09 0.01
Stochastic Oscillator 53.46 73.73

Price Performance

Historical Comparison
SCSC
IOVA

About SCSC ScanSource Inc.

ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: